Effects of the Oral Administration of Mosapride Citrate on Capsule Endoscopy Completion Rate

• Published in: Gut and liver Vol. 6; no. 3; pp. 339 - 343
• Main Authors: Yosuke Ida, Naoki Hosoe, Hiroyuki Imaeda, Rieko Bessho, Riko Ichikawa, Makoto Naganuma, Takanori Kanai, Toshifumi Hibi, Haruhiko Ogata
• Format: Journal Article
• Language: Korean
• Published: 대한간학회 30.06.2012
• Subjects: Capsule endoscopy; Mosapride; Prokinetics
• ISSN: 1976-2283

Background/Aims: In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion. Meth-ods: In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitaliza-tion, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time. Results: The univariate analysis showed that oral mo-sapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mo-sapride citrate (odds ratio [OR], 1.99; 95% confidence inter-val [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT). Conclusions: Oral mosapride ci-trate reduced the GTT and SBTT during CE and improved the CE completion rate. (Gut Liver 2012;6:339-343)